Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
J Thromb Haemost ; 6(11): 1962-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18752579

ABSTRACT

BACKGROUND: Vascular endothelial growth factor (VEGF) and histamine induce von Willebrand factor (VWF) release from vascular endothelial cells. Protein kinase C (PKC) is involved in the control of exocytosis in many secretory cell types. OBJECTIVES: We investigated the role of PKC and the interactions between PKC and Ca2+ signaling in both VEGF-induced and histamine-induced VWF secretion from human umbilical vein endothelial cells (HUVECs). RESULTS: Several PKC inhibitors (staurosporine, Ro31-8220, myristoylated PKC peptide inhibitor and Go6983) block VEGF-induced but not histamine-induced VWF secretion. PKC-alpha and novel PKCs (PKC-delta, PKC-epsilon, and PKC-eta), but not PKC-beta, are expressed in HUVECs. Both VEGF and histamine activate PKC-delta. However, gene inactivation experiments using small interfering RNA indicate that PKC-delta (but not PKC-alpha) is involved in the regulation of VEGF-induced but not histamine-induced secretion. Both VEGF and histamine induce a rise in cytosolic free Ca2+ ([Ca2+]c), but the response to VEGF is weaker and even absent in a significant subset of cells. Furthermore, VEGF-induced secretion is largely preserved when the rise in [Ca2+]c is prevented by BAPTA-AM. CONCLUSIONS: Our study identifies striking agonist specificities in signal-secretion coupling. Histamine-induced secretion is dependent on [Ca2+]c but not PKC, whereas VEGF-induced secretion is largely dependent on PKC-delta and significantly less on [Ca2+]c. Our data firmly establish the key role of PKC-delta in VEGF-induced VWF release, but suggest that a third, VEGF-specific, signaling intermediate is required as a PKC-delta coactivator.


Subject(s)
Endothelial Cells/metabolism , Histamine/pharmacology , Protein Kinase C-delta/metabolism , Vascular Endothelial Growth Factor A/physiology , von Willebrand Factor/metabolism , Calcium Signaling , Cells, Cultured , Endothelium, Vascular/cytology , Humans , Vascular Endothelial Growth Factor A/pharmacology
2.
J Thromb Haemost ; 4(7): 1588-95, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16839358

ABSTRACT

OBJECTIVE: von Willebrand factor (VWF) is acutely released from endothelial cells in response to numerous calcium-raising agents (e.g. thrombin, histamine) and cAMP-raising agents (e.g. epinephrine, adenosine, vasopressin). In contrast, very few inhibitors of endothelial VWF secretion have been described. The neurotransmitter dopamine is a modulator of exocytosis in several endocrine cells, and is possibly involved in the regulation of several endothelial cell functions. We therefore investigated the effect of dopamine on endothelial VWF secretion. RESULTS: Dopamine, D2/D3- and D4-specific agonists inhibited histamine- but not thrombin-induced VWF secretion. Expression of dopamine D2, D3 and D4 receptors was demonstrated by reverse transcription polymerase chain reaction (RT-PCR) in both human aortic (HAEC) and umbilical vein (HUVEC) endothelial cells. D2-D4 agonists did not inhibit histamine-induced rise in [Ca(2+)](i): they inhibited histamine-induced secretion even in the absence of extracellular calcium. Thus, the dopamine effects are not mediated by [Ca(2+)](i)-dependent signalling. D2/D3- and D4-specific agonists inhibited neither the rise in cAMP nor VWF secretion in response to epinephrine and adenosine, arguing against an effect on cAMP-mediated signalling. D1 and D5 receptors were not detected in HAEC or HUVEC by RT-PCR, and the D1/D5-specific agonist SKF 38 393 failed to modulate VWF secretion, arguing against a role for these receptors in endothelial exocytosis. CONCLUSIONS: Dopamine inhibits histamine-induced endothelial exocytosis by activating D2-D4 receptor, via a mechanism distinct from [Ca(2+)](i)-or cAMP-mediated signaling. In contrast, D1 and D5 receptors are not functionally expressed in cultured endothelial cells. Dopamine agonists may be useful as inhibitors of endothelial activation in inflammation and cardiovascular disease.


Subject(s)
Dopamine/physiology , Endothelial Cells/metabolism , Receptors, Dopamine/physiology , von Willebrand Factor/metabolism , Aorta/cytology , Cells, Cultured , Dopamine Agonists/pharmacology , Endothelium, Vascular/cytology , Exocytosis , Histamine , Humans , Receptors, Dopamine D2/physiology , Receptors, Dopamine D3/physiology , Receptors, Dopamine D4/physiology , Signal Transduction , Umbilical Veins/cytology
3.
Biochem Biophys Res Commun ; 270(1): 240-6, 2000 Apr 02.
Article in English | MEDLINE | ID: mdl-10733934

ABSTRACT

Apomine (SR-45023A) is a new antineoplastic compound which is currently in clinical trials and representative of the family of cholesterol synthesis inhibitors 1,1-bisphosphonate esters. Apomine inhibits growth of a wide variety of tumor cell lines with IC(50) values ranging from 5 to 14 microM. The antiproliferative activity of apomine was studied in comparison with that of other inhibitors of the mevalonate/isoprenoid pathway of cholesterol synthesis, simvastatin, farnesol, and 25-hydroxycholesterol. All these compounds inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity. Apomine (IC(50) = 14 microM), simvastatin (IC(50) = 3 microM), farnesol (IC(50) = 60 microM), and 25-hydroxycholesterol (IC(50) = 2 microM) inhibited HL60 cell growth. Growth inhibition due to simvastatin was reverted by mevalonate, whereas the antiproliferative activity of apomine, farnesol, and 25-hydroxycholesterol was not. Apomine triggered apoptosis in HL60 cells in less than 2 h. Apomine and farnesol induced caspase-3 activity at concentrations similar to their IC(50) values for cell proliferation, whereas a 10-fold excess of simvastatin was necessary to trigger apoptosis compared to its potency on proliferation. Caspase-3 activity was not induced by 25-hydroxycholesterol. The overall similar profile on mevalonate synthesis inhibition, cell growth inhibition, and apoptosis suggests that apomine acts as a synthetic mimetic of farnesol.


Subject(s)
Anticholesteremic Agents/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis , Diphosphonates/pharmacology , Farnesol/pharmacology , Cell Division/drug effects , Dose-Response Relationship, Drug , Humans , Hydroxycholesterols/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Mevalonic Acid/metabolism , Molecular Mimicry , Simvastatin/pharmacology , Terpenes/metabolism , Tumor Cells, Cultured
4.
Pediatrie ; 43(1): 31-3, 1988.
Article in French | MEDLINE | ID: mdl-3387178

ABSTRACT

A case of lethal acute congenital tuberculosis is reported in a 3-week-old infant who presented a crural adenopathy. An acute miliary pulmonary tuberculosis with extensive cutaneous reaction to tuberculin then appeared. Mycobacterium tuberculosis was found in the node and in urines. Specific treatment was ineffective and the child died within 5 weeks because of extensive lung lesions. A patent pulmonary tuberculosis was discovered in a grandmother that could not be incriminated to contamination because the incubation period was too short and the germ was of different type. A foetopathy could have been transmitted by the mother, who previously had a pulmonary tuberculosis, without late genital localisation. Therefore, a transient bacteriema from an enclosed older lung lesion in the mother may be evoked. A preventive treatment and a tight survey must be undertaken for a next pregnancy.


Subject(s)
Tuberculosis/congenital , Acute Disease , Humans , Infant, Newborn , Male , Tuberculosis/etiology , Tuberculosis, Lymph Node/congenital , Tuberculosis, Miliary/congenital , Tuberculosis, Urogenital/congenital
SELECTION OF CITATIONS
SEARCH DETAIL
...